Northwest Biotherapeutics (NWBO) Other Non-Current Liabilities (2013 - 2026)

Northwest Biotherapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $38.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 17.91% year-over-year to $38.7 million; the TTM figure through Mar 2026 stood at $38.7 million (down 17.91% YoY), while the FY2025 annual figure was $47.1 million, up 1.95% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $38.7 million, down from $47.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $107.9 million in Q1 2022, with the low at $10.0 million in Q2 2023.
• The 5-year median for Other Non-Current Liabilities is $46.2 million (2024), against an average of $46.6 million.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities tumbled 90.29% in 2023, then soared 154.95% in 2024.
• Northwest Biotherapeutics' Other Non-Current Liabilities stood at $90.7 million in 2022, then tumbled by 74.22% to $23.4 million in 2023, then surged by 97.4% to $46.2 million in 2024, then gained by 1.95% to $47.1 million in 2025, then dropped by 17.75% to $38.7 million in 2026.
• Business Quant data shows NWBO's Other Non-Current Liabilities at $38.7 million in Q1 2026, $47.1 million in Q4 2025, and $60.8 million in Q3 2025.